Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells.
- Author:
Ji Min LEE
1
;
Hyoung Won BAE
;
Sang Yeop LEE
;
Gong Je SEONG
;
Chan Yun KIM
Author Information
- Publication Type:Original Article
- Keywords: Anti-vascular endothelial growth factor; Bevacizumab; Oxidative stress; Retinal ganglion cell; RGC-5
- MeSH: Bevacizumab; Blotting, Western; Endothelial Growth Factors*; Hydrogen Peroxide; In Vitro Techniques; L-Lactate Dehydrogenase; Oxidative Stress; Real-Time Polymerase Chain Reaction; Receptors, Vascular Endothelial Growth Factor; Retinal Ganglion Cells*; Retinaldehyde*; Staurosporine; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2
- From:Korean Journal of Ophthalmology 2017;31(4):360-365
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To investigate the effects of anti-vascular endothelial growth factor (VEGF) antibody on the survival of retinal ganglion cell (RGC)-5 cells differentiated with staurosporine under oxidative stress. METHODS: We used real-time polymerase chain reaction and Western blot to confirm the expression of VEGF, VEGF receptor (VEGFR)-1 and VEGFR-2 in RGC-5 cells differentiated with staurosporine for 6 hours. The differentiated RGC-5 cells were treated with 800 µM hydrogen peroxide (H₂O₂) for 24 hours to induce oxidative stress. Then, the survival rate of RGC-5 was confirmed by lactate dehydrogenase assay at each concentration (0, 0.01, 0.1, and 1 mg) using bevacizumab as the anti-VEGF antibody. The expression of VEGF, VEGFR-1, and VEGFR-2 was confirmed using real-time polymerase chain reaction. RESULTS: VEGF, VEGFR-1, and VEGFR-2 were all expressed in differentiated RGC-5 cells. When RGC-5 cells were simultaneously treated with bevacizumab and 800 µM H₂O₂, survival of RGC-5 decreased with bevacizumab concentration. VEGF expression in RGC-5 cells increased with increasing concentration of bevacizumab. Similar patterns were observed for VEGFR-1 and VEGFR-2, but the degree of increase was smaller than that for VEGF. CONCLUSIONS: When bevacizumab was administered to differentiated RGC-5 cells, the cell damage caused by oxidative stress increased. Therefore, given these in vitro study results, caution should be exercised with bevacizumab treatment.
